13 Biotech Stocks with Huge Upside Potential

2. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Analysts’ Upside Potential as of June 9: 112.45%

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is now under Stifel’s coverage, with a buy rating and a $44 price target.

According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core asset, obicetrapib, has the potential to differentiate itself in the growing lipid-lowering market, according to Stifel.

The analyst points out that obicetrapib potentially differs from earlier attempts in the CETP inhibitor market due to the company’s cardiovascular outcomes trial, PREVAIL. Stifel anticipates significant upside even under cautious commercial assumptions.

The CETP inhibitor obicetrapib, which is being developed by NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), is intended to decrease cholesterol in the treatment of cardiovascular disease. Stifel cites the PREVAIL study and an extensive amount of supporting data to show that obicetrapib differs significantly from previous CETP failures. New Amsterdam has a legitimate route to market access due to this distinction and impending regulatory milestones.

Stifel’s $44 price estimate shows that they are confident in the drug’s clinical uniqueness and market potential.